Takamizawa Shigemasa, Shoji Hirokazu, Hirano Hidekazu, Izutsu Koji, Yamamoto Shun, Iwasa Satoru, Honma Yoshitaka, Okita Natsuko, Takashima Atsuo, Kato Ken, Boku Narikazu
Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Case Rep Oncol. 2021 Feb 25;14(1):85-89. doi: 10.1159/000512821. eCollection 2021 Jan-Apr.
Severe thrombocytopenia is a rare adverse event of panitumumab. Here, we report the first patient with metastatic colorectal cancer who developed severe thrombocytopenia, diagnosed as panitumumab-associated drug-induced immune thrombocytopenia (DITP). A clinical diagnosis of DITP can be obtained by excluding other causes of thrombocytopenia and is confirmed by the recovery of thrombocytopenia after the discontinuation of the suspected drug. Treatment includes permanent discontinuation of the suspected drug. Re-exposure should be avoided. It should be kept in mind that panitumumab can induce DITP in the case of a new, sudden, unexpected, and isolated drop in platelet count after excluding other causes of thrombocytopenia.
严重血小板减少是帕尼单抗罕见的不良事件。在此，我们报告首例转移性结直肠癌患者发生严重血小板减少，诊断为帕尼单抗相关药物性免疫性血小板减少症（DITP）。DITP的临床诊断可通过排除血小板减少的其他原因获得，并通过停用可疑药物后血小板减少症的恢复得以证实。治疗包括永久停用可疑药物。应避免再次暴露。需要牢记的是，在排除血小板减少的其他原因后，若血小板计数出现新的、突然的、意外的且孤立性下降，帕尼单抗可诱发DITP。
